C, control group

  • 文章类型: Journal Article
    抗精神病药物(APD)用于治疗精神疾病。然而,这些药物也可能导致一些发育和行为障碍。据报道,评估许多非典型抗精神病药的毒性作用的当代研究在哺乳动物和线虫中以可变剂量引起行为改变。利培酮,印度第二大处方药,需要更多探索其对人类的不利影响。这里,我们在秀丽隐杆线虫模型中探索利培酮暴露对摄食行为和运动模式的影响。除了预期的药理作用外,该研究的目标是研究利培酮暴露对进食和运动行为的毒性作用。将N2野生型菌株在液体培养测定中暴露2、4、6、8、10和12小时,具有固定的50μM浓度。由于咽泵的抑制作用以时间依赖性方式从11.05%-45.67%变化,因此喂养行为被耗尽。运动测定的结果还显示,与对照组相比,逆转(4.9%-34.03%)和欧米茄弯曲(26.23%-62.17%)的时变增加,而转弯计数(29.07%-42.2%)和蠕动速度(31.38%-42.22%)减少。目前的工作表明,在秀丽隐杆线虫中,由于利培酮暴露(50µM)而引起的行为改变是时间依赖性的。该研究得出结论,利培酮在秀丽隐杆线虫中的暴露会随着时间的推移产生毒性作用,可能是由于除5-羟色胺(5-H2T)和多巴胺(D2)以外的其他受体拮抗作用而引起的。
    Antipsychotic drugs (APDs) are prescribed for the treatment of psychiatric illness. However, these drugs can also contribute to several developmental and behavioral disorders. Contemporary studies to evaluate the toxic effects of numerous atypical antipsychotics are reported to cause behavioral alteration at variable doses in mammals and nematodes. Risperidone, the second most prescribed drug in India, requires more exploration of its adverse effects on humans. Here, we explore effects on feeding behavior and locomotion patterns due to risperidone exposure in C. elegans model. The study targets to work out the toxic effects of risperidone exposure on feeding and locomotion behavior in addition to the expected pharmacological effects. N2 wild type strain was exposed in liquid culture assay for 2, 4, 6, 8, 10, and 12 hours with fixed 50 µM concentration. Feeding behavior was depleted due to inhibition in pharyngeal pumping varying from 11.05% - 45.67% in a time-dependent manner. Results of locomotion assay also show time-varying increase in reversals (4.9%-34.03%) and omega bends (26.23%-62.17%) with reduction in turn counts (29.07%- 42.2%) and peristaltic speed (31.38%-42.22%) amongst exposed groups as to control. The present work shows behavioral alterations due to risperidone exposure (50 µM) in C. elegans is in a time-dependent manner. The study concludes that risperidone exposure in C. elegans produces toxic effects with time, possibly caused by antagonizing other receptors apart from serotonin (5-H2T) and dopamine (D2) adding to its expected pharmacological effects.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    糖尿病肾病(DN)是糖尿病的严重并发症,是终末期肾病的主要病因,这给全世界的人类社会造成了严重的健康问题和巨大的经济负担。常规战略,如肾素-血管紧张素-醛固酮系统阻断,血糖水平控制,和减轻体重,在许多DN管理的临床实践中,可能无法获得令人满意的结果。值得注意的是,由于多目标函数,中药作为DN治疗的主要或替代疗法具有很好的临床益处。越来越多的研究强调确定中药的生物活性化合物和肾脏保护作用的分子机制。参与糖/脂代谢调节的信号通路,抗氧化,抗炎,抗纤维化,足细胞保护已被确定为重要的作用机制。在这里,在回顾临床试验结果后,我们总结了中药及其生物活性成分在治疗和管理DN中的临床疗效,系统评价,和荟萃分析,对动物和细胞实验中报道的相关潜在机制和分子靶标进行了彻底讨论。我们旨在全面了解中药对DN的保护作用。
    Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    药物代谢组学已成功用于一种特定不良反应的毒性预测。然而在临床实践中,两种或两种以上不同的毒性总是相互伴随,这对药物代谢组学提出了新的挑战。胃肠道毒性和骨髓抑制是伊立替康(CPT-11)引起的两种主要不良反应,并且经常表现出很大的个体差异。在目前的研究中,我们进行了一项药物代谢组学研究,目的是筛选给药前血清中可同时预测迟发性腹泻和CPT-11骨髓抑制的唯一生物标志物.根据迟发性腹泻症状判断胃肠道毒性和骨髓抑制的严重程度和敏感性差异,组织病理学检查,相对细胞因子和血细胞计数。顺序进行基于质谱的非靶向和靶向代谢组学,以解剖给药前血清中的代谢物特征。最终,使用二元logistic回归分析筛选出两组代谢物作为晚发性腹泻和骨髓抑制个体差异的预测因子,分别。将此结果与现有预测因子进行比较,并由另一个独立的外部验证集进行验证。我们的研究表明,根据给药前代谢谱,毒性预测是可能的。药物代谢组学可能是复杂的毒性预测的潜在有用工具。我们的发现也为CPT-11精准医学提供了新的见解。
    Pharmacometabolomics has been already successfully used in toxicity prediction for one specific adverse effect. However in clinical practice, two or more different toxicities are always accompanied with each other, which puts forward new challenges for pharmacometabolomics. Gastrointestinal toxicity and myelosuppression are two major adverse effects induced by Irinotecan (CPT-11), and often show large individual differences. In the current study, a pharmacometabolomic study was performed to screen the exclusive biomarkers in predose serums which could predict late-onset diarrhea and myelosuppression of CPT-11 simultaneously. The severity and sensitivity differences in gastrointestinal toxicity and myelosuppression were judged by delayed-onset diarrhea symptoms, histopathology examination, relative cytokines and blood cell counts. Mass spectrometry-based non-targeted and targeted metabolomics were conducted in sequence to dissect metabolite signatures in predose serums. Eventually, two groups of metabolites were screened out as predictors for individual differences in late-onset diarrhea and myelosuppression using binary logistic regression, respectively. This result was compared with existing predictors and validated by another independent external validation set. Our study indicates the prediction of toxicity could be possible upon predose metabolic profile. Pharmacometabolomics can be a potentially useful tool for complicating toxicity prediction. Our findings also provide a new insight into CPT-11 precision medicine.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    In the evaluation of vaccine seroresponse rates and adverse reaction rates, extreme test results often occur, with substantial adverse event rates of 0% and/or seroresponse rates of 100%, which has produced several data challenges. Few studies have used both the Bayesian and frequentist methods on the same sets of data that contain extreme test cases to evaluate vaccine safety and immunogenicity. In this study, Bayesian methods were introduced, and the comparison with frequentist methods was made based on practical cases from randomized controlled vaccine trials and a simulation experiment to examine the rationality of the Bayesian methods. The results demonstrated that the Bayesian non-informative method obtained lower limits (for extreme cases of 100%) and upper limits (for extreme cases of zero), which were similar to the limits that were identified with the frequentist method. The frequentist rate estimates and corresponding confidence intervals (CIs) for extreme cases of 0 or 100% always equaled and included 0 or 100%, respectively, whereas the Bayesian estimations varied depending on the sample size, with none equaling zero or 100%. The Bayesian method obtained more reasonable interval estimates of the rates with extreme data compared with the frequentist method, whereas the frequentist method objectively expressed the outcomes of clinical vaccine trials. The two types of statistical results are complementary, and it is proposed that the Bayesian and frequentist methods should be combined to more comprehensively evaluate clinical vaccine trials.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号